Kodiak Sciences Shares Surge After Positive Clinical Trial Results
Shares of Kodiak Sciences (NASDAQ: KOD) surged by over 177% on Monday following the announcement that two investigational drug candidates, Zenkuda and KSI-501, met their primary endpoints in a Phase 3 clinical trial for wet age-related macular degeneration. The results showed rapid therapeutic effects with long-lasting benefits and favorable safety profiles. Kodiak plans to file a Biologics License Application (BLA) for Zenkuda later this year as it moves toward potential commercialization. CEO Victor Perlroth highlighted the significance of these findings, positioning the company for its next stage in development within an estimated $32 billion global retinal drug market by 2030. The positive data has generated strong investor interest and could significantly impact Kodiak’s future growth trajectory as it seeks regulatory approval to bring Zenkuda to market.
Tickers: $KOD
Topics: clinical trial results FDA approval process stock price movement